Avenzo Therapeutics Announces Clinical Study Collaboration With Gilead Sciences To Evaluate AVZO-021 And Trodelvy In HR+/HER2- Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Avenzo Therapeutics is collaborating with Gilead Sciences to evaluate a combination therapy of AVZO-021 and Trodelvy in HR+/HER2- metastatic breast cancer. Avenzo will sponsor the trial, while Gilead provides Trodelvy. The study is part of an ongoing Phase 1/2 trial, with combination cohorts starting in Q4 2024.
September 03, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences is collaborating with Avenzo Therapeutics to evaluate Trodelvy in combination with AVZO-021 for HR+/HER2- metastatic breast cancer. Gilead will provide Trodelvy for the trial.
The collaboration with Avenzo Therapeutics to evaluate Trodelvy in a new combination therapy could enhance Gilead's oncology portfolio and potentially lead to new treatment options, positively impacting Gilead's stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80